Upstream Bio (UPB) Revenue & Revenue Breakdown
Upstream Bio Revenue Highlights
Latest Revenue (Y)
$2.37M
Latest Revenue (Q)
$566.00K
Upstream Bio Revenue by Period
Upstream Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $2.37M | -0.42% |
| 2023-12-31 | $2.38M | 96.37% |
| 2022-12-31 | $1.21M | - |
Upstream Bio generated $2.37M in revenue during NA 2024, up -0.42% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Upstream Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $566.00K | -7.67% |
| 2024-12-31 | $613.00K | 0.99% |
| 2024-09-30 | $607.00K | 19.02% |
| 2024-06-30 | $510.00K | -20.31% |
| 2024-03-31 | $640.00K | 42.22% |
| 2023-12-31 | $450.00K | -27.54% |
| 2023-09-30 | $621.00K | - |
Upstream Bio generated $566.00K in revenue during Q1 2025, up -7.67% compared to the previous quarter, and up 125.78% compared to the same period a year ago.
Upstream Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NKTR | Nektar Therapeutics | $98.43M | $10.46M |
| PHAT | Phathom Pharmaceuticals | $55.25M | $39.50M |
| RLAY | Relay Therapeutics | $10.01M | $7.68M |
| PRAX | Praxis Precision Medicines | $8.55M | - |
| DNTH | Dianthus Therapeutics | $6.24M | $1.16M |
| ZBIO | Zenas BioPharma | $5.00M | $10.00M |
| PRME | Prime Medicine | $2.98M | $1.11M |
| UPB | Upstream Bio | $2.37M | $566.00K |
| SEPN | Septerna | $1.07M | $219.00K |
| OCS | Oculis | $883.00K | - |
| BCAX | Bicara Therapeutics | - | - |